Market by Mechanism, Indicator, Consumer, Commodity, and Country Outlook | Forecast 2022-2028
Based on Triton’s report, the companion diagnostics market in North America is assessed to advance with a CAGR of 12.96% during the forecasting years 2022-2028.
Report scope can be customized per your requirements. Request For CustomizationÂ
The
countries studied in the region consist of:
•       Â
The United States
•       Â
Canada
In
North America, the US holds the major share in the companion diagnostics market. The surged focus on precision medicine for
various therapeutic applications plays a crucial role in fueling the studied
market’s growth. Also, the increasing prevalence of chronic conditions, such as
diabetes and cardiovascular disease, has fueled investment in the companion
diagnostics market. Furthermore, the rising incidence of neurodegenerative
diseases is expected to surge the demand for innovative diagnostics services,
thereby driving the companion diagnostics market.
In recent years, the region has witnessed a rise
in health consciousness and governments’ rollout of healthcare plans. In the
United States, the vast network between service providers and manufacturers
contributes to the development of innovative diagnostics solutions. There is
also development in favor of a single and comprehensive CDx, encouraging the
progression of the companion diagnostics market.
Other than this, the support by the FDA in terms
of the development of a flexible regulatory pathway helps the deployment of
various medical devices, including companion diagnostics. Such developments
undertaken by the government is expected to widen the scope and growth of the
companion diagnostics market.
In the market, assay kits and reagents are used
to qualitatively detect, assess, and analyze various protein types in human
tissue in order to use targeted drugs. In this regard, companion diagnostics
assay kits and reagents support the laboratory achieve timely results through
ready-to-use solutions. The market’s segmentation includes commodity,
mechanism, indicator, and consumer. The commodity section consists of assay
kits and reagents and software and services.
Some
of the companies in the market comprise Danaher Corporation, Sysmex
Corporation, Myriad Genetics, Qiagen, Genomic Health, and Roche Diagnostics.
Danaher Corporation designs and manufactures
professional, medical, industrial, and commercial products. It majorly focuses
on developing applications for environmental and applied solutions, life
sciences, and medical diagnostics. The company’s product portfolio entails
microsystems for research, analytical instruments, reagents, consumables,
software, and disinfection systems, among others. Danaher operates through a
network of manufacturing, sales, service, and distribution facilities. It is
headquartered in Washington, DC, the US.
Key deliverables of the report:
â—ŹÂ Â Â Â Â Market CAGR during the forecasting years 2022-2028
â—ŹÂ Â Â Â Â Detailed data highlighting key insights, industry components, and market strategies
â—ŹÂ Â Â Â Comprehensive information and estimation of the companion diagnostics market revenue growth in North America and its influence on the parent market
â—ŹÂ Â Â Â Â In-depth study of forthcoming trends in consumer behavioral patterns
●     A meticulous analysis of the competitive landscape, vendor scorecard, and Porter’s Five Forces
â—ŹÂ Â Â Â A wide-ranging study of factors that will challenge the NA
companion diagnostics market’s growth during the upcoming years
Want to get specific insights? Our team of
analysts can customize this report based on your preferences. Connect with us here.Â
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. NORTH
AMERICA COMPANION DIAGNOSTICS MARKET - SUMMARY
2. INDUSTRY
OUTLOOK
2.1. IMPACT
OF COVID-19 ON THE COMPANION DIAGNOSTICS MARKET
2.2. KEY
INSIGHTS
2.2.1. COMMERCIAL
SUCCESS OF PRECISION MEDICINE TREATMENT
2.2.2. ADOPTION
OF PREDICTIVE BIOMARKERS
2.2.3. FUSION
OF COMPUTER SCIENCE AND BIOLOGY
2.3. PORTER’S
FIVE FORCES ANALYSIS
2.3.1. THREAT
OF NEW ENTRANTS
2.3.2. THREAT
OF SUBSTITUTES
2.3.3. BARGAINING
POWER OF BUYERS
2.3.4. BARGAINING
POWER OF SUPPLIERS
2.3.5. THREAT
OF COMPETITIVE RIVALRY
2.4. KEY
BUYING IMPACT ANALYSIS
2.4.1. COST
2.4.2. AVAILABILITY
2.4.3. SENSITIVITY
& SPECIFICITY
2.4.4. EFFICACY
2.5. MARKET
ATTRACTIVENESS INDEX
2.6. VENDOR
SCORECARD
2.7. INDUSTRY
COMPONENTS
2.8. REGULATORY
FRAMEWORK
2.9. KEY
MARKET STRATEGIES
2.9.1. ACQUISITIONS
2.9.2. PRODUCT
LAUNCHES
2.9.3. CONTRACTS
& AGREEMENTS
2.10. MARKET
DRIVERS
2.10.1. INCREASE
IN INCIDENCE OF MEDICATION REACTIONS
2.10.2. INCREASING
PREVALENCE OF CANCER CASES AND FATALITIES
2.10.3. RISING
PREVALENCE OF PRECISION MEDICINES
2.11. MARKET
CHALLENGES
2.11.1. WEAK
REIMBURSEMENT FRAMEWORK
2.11.2. COMMON
CASES OF LEAKAGE IN ONCOLOGY COMPANION DIAGNOSTICS
2.12. MARKET
OPPORTUNITY
2.12.1. ONGOING
RESEARCH AND INVESTMENTS IN NEXT GENERATION GENE-SEQUENCING
3. NORTH
AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK - BY MECHANISM
3.1. IN-SITU
HYBRIDIZATION
3.2. POLYMERASE
CHAIN REACTION
3.3. IMMUNOHISTOCHEMISTRY
3.4. NEXT
GENERATION SEQUENCING
3.5. OTHER
MECHANISMS
4. NORTH
AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK - BY INDICATOR
4.1. ONCOLOGY
4.2. NEUROLOGY
4.3. INFECTIOUS
DISEASES
4.4. OTHER
INDICATORS
5. NORTH
AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK - BY CONSUMER
5.1. PHARMACEUTICAL
AND BIOPHARMACEUTICAL COMPANIES
5.2. REFERENCE
LABORATORIES
5.3. OTHER
CONSUMERS
6. NORTH
AMERICA COMPANION DIAGNOSTICS MARKET OUTLOOK - BY COMMODITY
6.1. ASSAY
KITS AND REAGENTS
6.2. SOFTWARE
AND SERVICES
7. NORTH AMERICA
COMPANION DIAGNOSTICS MARKET - COUNTRY OUTLOOK
7.1. UNITED
STATES
7.2. CANADA
8. COMPETITIVE
LANDSCAPE
8.1. ABBOTT
LABORATORIES
8.2. ALMAC
GROUP
8.3. ARUP
LABORATORIES
8.4. BIOCARTIS
8.5. BIOMERIEUX
8.6. DANAHER
CORPORATION
8.7. GE
HEALTHCARE
8.8. GENOMIC
HEALTH
8.9. ILLUMINA
INC
8.10. MYRIAD
GENETICS
8.11. QIAGEN
8.12. ROCHE
DIAGNOSTICS
8.13. SYSMEX
CORPORATION
8.14. THERMO
FISHER SCIENTIFIC
8.15. AGILENT
9. RESEARCH
METHODOLOGY & SCOPE
9.1. RESEARCH
SCOPE & DELIVERABLES
9.2. SOURCES
OF DATA
9.3. RESEARCH
METHODOLOGY
TABLE 1: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: LIST OF ACQUISITIONS
TABLE 4: LIST OF PRODUCT
LAUNCHES
TABLE 5: LIST OF CONTRACTS
& AGREEMENTS
TABLE 6: NUMBER OF CANCER
PATIENTS IN 2020
TABLE 7: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2022-2028 (IN $ MILLION)
TABLE 8: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2022-2028 (IN $ MILLION)
TABLE 9: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2022-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2022-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
FIGURE 1: MARKET
ATTRACTIVENESS INDEX
FIGURE 2: INDUSTRY COMPONENTS
FIGURE 3: FDA FRAMEWORK
FIGURE 4: CDX LEAKAGE POINTS
FIGURE 5: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY MECHANISM, 2021 & 2028 (IN %)
FIGURE 6: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY IN-SITU HYBRIDIZATION, 2022-2028 (IN $ MILLION)
FIGURE 7: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2028 (IN $
MILLION)
FIGURE 8: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2028 (IN $ MILLION)
FIGURE 9: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2028 (IN $
MILLION)
FIGURE 10: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY OTHER MECHANISMS, 2022-2028 (IN $ MILLION)
FIGURE 11: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY INDICATOR, 2021 & 2028 (IN %)
FIGURE 12: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2028 (IN $ MILLION)
FIGURE 13: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2028 (IN $ MILLION)
FIGURE 14: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 15: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATORS, 2022-2028 (IN $ MILLION)
FIGURE 16: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY CONSUMER, 2021 & 2028 (IN %)
FIGURE 17: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL
COMPANIES, 2022-2028 (IN $ MILLION)
FIGURE 18: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2028 (IN $
MILLION)
FIGURE 19: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY OTHER CONSUMERS, 2022-2028 (IN $ MILLION)
FIGURE 20: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, OUTLOOK BY COMMODITY, 2021 & 2028 (IN %)
FIGURE 21: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2028 (IN $
MILLION)
FIGURE 22: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, BY SOFTWARE AND SERVICES, 2022-2028 (IN $
MILLION)
FIGURE 23: NORTH AMERICA
COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2028 (IN %)
FIGURE 24: UNITED STATES
COMPANION DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)
FIGURE 25: CANADA COMPANION
DIAGNOSTICS MARKET 2022-2028 (IN $ MILLION)